Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Conditions

• Carcinoid Tumor
• Pancreatic Neuroendocrine Tumor

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Cabozantinib — DRUG
  60 mg QD orally in cycles of 28 days

Study Details

Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.

Key Dates

Start date

Jul 31, 2012

Status verified

Mar 2024

Primary completion

Aug 31, 2021

Completion

Dec 31, 2023

Study Design

Enrollment

61 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Metastatic or Unresectable PNET
  An anticipated 35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
• Experimental: Metastatic or Unresectable Carcinoid
  An anticipated 35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Imaging was performed cycles 2,4,6 every 8 weeks for the first 24 weeks, then every 3rd cycle every 12 weeks until progression or EOT. Median treatment duration was 8 cycles for the Carcinoid cohort and 12.5 cycles for the PNET cohort. Cycle=28 days. ]

Locations (2)

Find similar trials in Boston, MA

Related Studies

• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
  PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Los Angeles, California
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
  PHASE3 · Recruiting · RayzeBio, Inc. · Phoenix, Arizona
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  PHASE1 · Recruiting · Anusha Kalbasi · Duarte, California
• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
  Recruiting · Cedars-Sinai Medical Center · Los Angeles, California